SCS
AMLX icon

Sound Capital Solutions’s Amylyx Pharmaceuticals AMLX Stock Holding History

Sound Capital Solutions’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$573K Buy
+31,890
New +$493K 0.13% 121

Other funds holding AMLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Sound Capital Solutions's AMLX Position: Q2 2026 in Review

Sound Capital Solutions opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 31,890 shares worth $573K. The stake represents 0.13% of the portfolio and ranks #121 among its holdings.

182 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Sound Capital Solutions held 31,890 shares of Amylyx Pharmaceuticals worth $573K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Sound Capital Solutions position in Q2 2026.
  • Amylyx Pharmaceuticals made up 0.13% of Sound Capital Solutions's portfolio in Q2 2026, its #121 holding.
  • 182 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Sound Capital Solutions's 13F filing for Q2 2026, filed 13 Aug 2026.